The AT(N) system for describing biological changes in Alzheimer's disease: a plain language summary.

IF 2.3 Q3 CLINICAL NEUROLOGY
Neurodegenerative disease management Pub Date : 2022-10-01 Epub Date: 2022-07-22 DOI:10.2217/nmt-2022-0013
Harald Hampel, Aya Elhage, Jeffrey Cummings, Kaj Blennow, Peng Gao, Clifford R Jack, Andrea Vergallo
{"title":"The AT(N) system for describing biological changes in Alzheimer's disease: a plain language summary.","authors":"Harald Hampel,&nbsp;Aya Elhage,&nbsp;Jeffrey Cummings,&nbsp;Kaj Blennow,&nbsp;Peng Gao,&nbsp;Clifford R Jack,&nbsp;Andrea Vergallo","doi":"10.2217/nmt-2022-0013","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a plain language summary of an article published in <i>Nature Reviews Neurology</i>. It explains how Alzheimer's disease is diagnosed. It also looks at whether a newer way to assess people with Alzheimer's disease could help improve how the condition is diagnosed, monitored, and treated.</p><p><strong>Why is this important?: </strong>Alzheimer's disease is a long-term progressive brain disease that leads to difficulties with thinking and memory. It is a progressive condition, which means it gets worse over time. Biological changes occur in the brain of people with Alzheimer's disease. This includes a build-up of toxic protein clusters called amyloid plaques and tau tangles, gradual damage to the brain cells (neurodegeneration), and brain shrinkage due to loss of neurons. It is often due to multiple factors and doctors usually diagnose Alzheimer's disease by looking at a person's symptoms and ruling out other causes of dementia. However, research shows that people diagnosed in this way do not always have the biological changes in the brain that are related to Alzheimer's disease. This means that some people may be misdiagnosed. Additionally, there may be a delay in the appearance of Alzheimer's symptoms, by which point changes in the brain may be severe. For example, people with Alzheimer's disease show biological changes in the brain, years before symptoms appear.</p><p><strong>What are the key takeaways?: </strong>An assessment of biological changes in the brain, by measuring substances that indicate disease progress (biomarkers), may offer a fuller picture of a person's Alzheimer's disease, how advanced it is, and which treatments are likely to work best. A recently developed classification scheme known as the AT(N) system provides a way to assess and describe the biological changes in amyloid (A), tau (T), and neurodegeneration (N) that occur in people with Alzheimer's disease. The goal is to include biomarker testing in clinical practice to help physicians and practitioners diagnose, monitor, and treat people with Alzheimer's disease more effectively. The AT(N) system is being used for various purposes in clinical studies, and has the potential to assist physicians and practitioners in early detection, accurate diagnosis, staging, and treatment selection for people with Alzheimer's disease.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2022-0013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/7/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

What is this summary about?: This is a plain language summary of an article published in Nature Reviews Neurology. It explains how Alzheimer's disease is diagnosed. It also looks at whether a newer way to assess people with Alzheimer's disease could help improve how the condition is diagnosed, monitored, and treated.

Why is this important?: Alzheimer's disease is a long-term progressive brain disease that leads to difficulties with thinking and memory. It is a progressive condition, which means it gets worse over time. Biological changes occur in the brain of people with Alzheimer's disease. This includes a build-up of toxic protein clusters called amyloid plaques and tau tangles, gradual damage to the brain cells (neurodegeneration), and brain shrinkage due to loss of neurons. It is often due to multiple factors and doctors usually diagnose Alzheimer's disease by looking at a person's symptoms and ruling out other causes of dementia. However, research shows that people diagnosed in this way do not always have the biological changes in the brain that are related to Alzheimer's disease. This means that some people may be misdiagnosed. Additionally, there may be a delay in the appearance of Alzheimer's symptoms, by which point changes in the brain may be severe. For example, people with Alzheimer's disease show biological changes in the brain, years before symptoms appear.

What are the key takeaways?: An assessment of biological changes in the brain, by measuring substances that indicate disease progress (biomarkers), may offer a fuller picture of a person's Alzheimer's disease, how advanced it is, and which treatments are likely to work best. A recently developed classification scheme known as the AT(N) system provides a way to assess and describe the biological changes in amyloid (A), tau (T), and neurodegeneration (N) that occur in people with Alzheimer's disease. The goal is to include biomarker testing in clinical practice to help physicians and practitioners diagnose, monitor, and treat people with Alzheimer's disease more effectively. The AT(N) system is being used for various purposes in clinical studies, and has the potential to assist physicians and practitioners in early detection, accurate diagnosis, staging, and treatment selection for people with Alzheimer's disease.

描述阿尔茨海默病生物学变化的AT(N)系统:简单的语言总结。
这个总结是关于什么的?这是一篇发表在《自然评论神经学》上的文章的简明扼要的总结。它解释了阿尔茨海默病的诊断方法。它还研究了一种评估阿尔茨海默病患者的新方法是否有助于改善这种疾病的诊断、监测和治疗方式。为什么这很重要?阿尔茨海默病是一种长期的进行性脑部疾病,会导致思考和记忆困难。这是一种进行性疾病,这意味着它会随着时间的推移而恶化。阿尔茨海默病患者的大脑会发生生物学变化。这包括被称为淀粉样斑块和tau蛋白缠结的有毒蛋白质簇的积累,对脑细胞的逐渐损伤(神经变性),以及由于神经元丧失而导致的大脑萎缩。它通常是由多种因素引起的,医生通常通过观察一个人的症状来诊断阿尔茨海默病,并排除痴呆症的其他原因。然而,研究表明,以这种方式诊断的人并不总是有与阿尔茨海默病相关的大脑生物学变化。这意味着有些人可能会被误诊。此外,阿尔茨海默病的症状可能会延迟出现,到那时大脑的变化可能会很严重。例如,患有阿尔茨海默病的人在症状出现前几年就表现出大脑的生物学变化。关键的收获是什么?通过测量指示疾病进展的物质(生物标志物)来评估大脑的生物变化,可以更全面地了解一个人的阿尔茨海默病,了解病情的进展程度,以及哪种治疗方法可能最有效。最近开发的分类方案称为AT(N)系统提供了一种评估和描述发生在阿尔茨海默病患者的淀粉样蛋白(A), tau (T)和神经变性(N)的生物学变化的方法。目标是将生物标志物测试纳入临床实践,以帮助医生和从业人员更有效地诊断、监测和治疗阿尔茨海默病患者。AT(N)系统在临床研究中被用于各种目的,并有可能帮助医生和从业人员对阿尔茨海默病患者进行早期发现、准确诊断、分期和治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
35
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信